does glp 1 not work for some people The promise and peril of GLP-1 agonists: What we do (and don't) know as of August 2024 Weight loss: What to do

These delays highlight the structural barriers that can slow adoption in populations with higher rates of comorbidities

Researchers at UC Irvine issue a warning that GLP-1RAs may be dangerous for children Source: UC Irvine School of Medicine Irvine, CA, August 28, 2023 A team of clinicians, exercise scientists, pharmaceutical scholars, ethicists and behavioral experts at the University of California, Irvine, outlined their concerns that the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for childrens health

Compared to classical exenatide given twice daily (BID, the once-weekly (QW) formulation at a 2 mg dose level provides a relatively stable plasma concentration at steady-state (300 pg/ml) because of the more continuous delivery of the drug, with equal (or slightly improved) efficacy on glycemic control and body weight after 24 and 30 wk of treatment [888]

To view a copy of this licence, visit About this article Cite this article Cedirian, S., Donati, M., Rapparini, L

Patients can also do nothing - usually improves over time

Should older adults be concerned about muscle loss with GLP-1 medications